STOCK TITAN

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it will host a live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results for the second quarter ended June 30, 2023, and provide a general business update.

Webcast Information
Date: Wednesday, August 9, 2023
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://lifescievents.com/event/belitebio/

Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available approximately two hours after the event for 90 days.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as Stargardt disease and Geographic Atrophy in advanced Age-Related Macular Degeneration, in addition to specific metabolic diseases. For more information, follow us on TwitterInstagramLinkedInFacebook or visit us at www.belitebio.com.

Media and Investor Relations Contacts
Jennifer Wu /ir@belitebio.com
Tim McCarthy /tim@lifesciadvisors.com


Belite Bio, Inc American Depositary Shares

NASDAQ:BLTE

BLTE Rankings

BLTE Latest News

BLTE Stock Data

1.27B
11.21M
60.29%
0.81%
0.13%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
San Diego

About BLTE

belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.